Latest News

Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story

20/07/2022
Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.

30/06/2022
Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer

London, 30 June, 2022 – Resolution Therapeutics announces the appointment of Dr. Amol Ketkar, as Chief Development Officer.

05/04/2022
Resolution Therapeutics and panCELLa Inc announce a Research Evaluation and Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease

London and Toronto, 5 April 2022 - Resolution Therapeutics partners with panCELLa to develop iPSC-derived macrophage cell therapy for inflammatory organ disease.

05/04/2022
Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd

London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease.

17/02/2022
Resolution Therapeutics Strengthens its Team with Two New Appointments

London, 17 February 2022 – Resolution Therapeutics announces the strengthening of its senior management team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance.

12/04/2021
Resolution Therapeutics Appoints Lisa Bright to its Board of Directors

London, 12 April 2021 – Resolution Therapeutics announces the appointment of Lisa Bright as a Non-Executive Director of the Company.

26/01/2021
Resolution: Fighting fibrosis with macrophages

Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.

02/12/2020
Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd

London, 2 December 2020 - Resolution Therapeutics announces the completion of a £26.6m Series A financing from Syncona Ltd.